Nanjing Leads Biolabs Income Statement

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Revenue	177.26	-	8.87
Cost of Revenue	-	-	3.19
Gross Profit	177.26	-	5.68
Selling, General & Admin	82.7	87.69	38.05
Research & Development	289.09	185.68	230.86
Operating Expenses	371.79	273.38	268.91
Operating Income	-194.53	-273.38	-263.23
Interest Expense	-7.19	-5.76	-1.4
Interest & Investment Income	29.56	8.29	6.55
Currency Exchange Gain (Loss)	-	2.04	2.77
Other Non Operating Income (Expenses)	-24.28	7.96	3.96
EBT Excluding Unusual Items	-196.43	-260.85	-251.35
Gain (Loss) on Sale of Investments	0.54	1.72	6.44
Other Unusual Items	-	-42.08	-117.33
Pretax Income	-195.89	-301.22	-362.25
Income Tax Expense	15.53	-	-
Net Income	-211.42	-301.22	-362.25
Net Income to Common	-211.42	-301.22	-362.25
Shares Outstanding (Basic)	174	150	145
Shares Outstanding (Diluted)	174	150	145
Shares Change (YoY)	16.10%	3.56%	-
EPS (Basic)	-1.21	-2.01	-2.50
EPS (Diluted)	-1.21	-2.01	-2.50
Free Cash Flow	-162.65	-121.79	-204.41
Free Cash Flow Per Share	-0.93	-0.81	-1.41
Gross Margin	100.00%	-	64.07%
Operating Margin	-109.75%	-	-2969.26%
Profit Margin	-119.27%	-	-4086.28%
Free Cash Flow Margin	-91.76%	-	-2305.84%
EBITDA	-178.9	-253.13	-243.49
EBITDA Margin	-100.92%	-	-
D&A For EBITDA	15.64	20.24	19.74
EBIT	-194.53	-273.38	-263.23
EBIT Margin	-109.75%	-	-